Orion Oyj (FI) - Change in Orion Group Executive Management Board as of 1 Oct 2010

Orion Oyj (FI) - Change in Orion Group Executive Management Board as of 1 Oct 2010

ESPOO, Finland, May 18, 2010-Mr. Pekka Kaivola, Senior Vice President responsible for the Global Sales line function of the Orion Group and member of the Executive Management Board of the Orion Group will retire on 31 December 2010. He will leave his present position as of 1 October 2010, continuing as Senior Advisor until his retirement and reporting to the President and CEO of Orion Corporation. When stepping down from the position of Senior Vice President responsible for the Global Sales line function, Mr. Kaivola will also step down from the Executive Management Board.

Mrs. Satu Ahomäki, M.Sc. (Econ.), currently Senior Vice President responsible for Orion's Animal Health business division and member of the Executive Management Board of the Orion Group, has been appointed Senior Vice President responsible for the Global Sales line function, as of 1 October 2010. Mrs. Ahomäki will continue as a member of the Executive Management Board also in her new position.

A new head who will report to a member of the Executive Management Board, will be appointed for the Animal Health business.

Timo Lappalainen, President and CEO, says:

"Pekka Kaivola has served the Orion Group since 1989, having successfully headed the company's sales operations which, under his management, have profitably evolved into a European-wide organization. I am happy to have him available for the company until the end of the year.

Satu Ahomäki is an experienced Orion colleague who has led the European expansion of our Animal Health business. Her experience from the different fields of pharmaceutical industry is important for us in the accelerating changes of the business."

The CV of Satu Ahomäki is available on the homepage of Orion, at www.orion.fi/emb-members<http://www.orion.fi/emb-members>.

Orion Corporation

Timo Lappalainen Olli Huotari President and CEO SVP, Corporate Functions

Contact person:

Timo Lappalainen, President and CEO, phone +358 50 966 3692

 

 

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo

Homepage: www.orion.fi<http://www.orion.fi/>

Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.

 

The Group's net sales in 2009 amounted to EUR 772 million. The Company invested EUR 95 million in research and development. At the end of 2009, the Group had a total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.